Early post-lung transplant cell-free DNA levels are associated with baseline lung allograft function

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10498660" target="_blank" >RIV/00064165:_____/25:10498660 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10498660 RIV/00216208:11130/25:10498660 RIV/00064203:_____/25:10498660

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=oZ5Hh_Oe7s" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=oZ5Hh_Oe7s</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.trim.2025.102245" target="_blank" >10.1016/j.trim.2025.102245</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Early post-lung transplant cell-free DNA levels are associated with baseline lung allograft function

Popis výsledku v původním jazyce

BACKGROUND: Baseline lung allograft dysfunction (BLAD) is defined as the failure to achieve normal pulmonary function-specifically, forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) values of &gt;=80 %-within the first year after lung transplantation. It is hypothesised that early subclinical injury, reflected by elevated donor-derived cell-free DNA (dd-cfDNA), both in absolute concentration and percentage (dd-cfDNA%), as well as total cell-free DNA (cfDNA), may be predictive of subsequent BLAD development. METHODS: We included patients who underwent bilateral lung transplantation between May 2021 and September 2023. Blood samples collected between 3 and 9 months post-transplantation were analysed for dd-cfDNA%, dd-cfDNA concentration (copies/mL), and estimated total cfDNA (copies/mL). BLAD was defined by failure to achieve both FEV1 and FVC &gt;=80 % of predicted values within the first year. RESULTS: A total of 158 samples from 37 patients were analysed. Ten patients (27 %) met the BLAD criteria. Those with BLAD had significantly higher dd-cfDNA levels (median: 39 cp/mL) compared to non-BLAD patients (26 cp/mL; p = 0.01). Similarly, total cfDNA levels were significantly elevated in the BLAD group (22,809 cp/mL vs. 13,840 cp/mL; p = 0.002). However, dd-cfDNA% did not differ significantly (0.23 % vs. 0.15 %; p = 0.2). CONCLUSION: Elevated absolute dd-cfDNA and total cfDNA levels in the early post-transplant period were associated with BLAD, suggesting that cfDNA may serve as a potential predictive biomarker. These findings support the potential of cfDNA-based biomarkers to enhance early detection of graft dysfunction, warranting validation in larger cohorts.

Název v anglickém jazyce

Early post-lung transplant cell-free DNA levels are associated with baseline lung allograft function

Popis výsledku anglicky

BACKGROUND: Baseline lung allograft dysfunction (BLAD) is defined as the failure to achieve normal pulmonary function-specifically, forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) values of &gt;=80 %-within the first year after lung transplantation. It is hypothesised that early subclinical injury, reflected by elevated donor-derived cell-free DNA (dd-cfDNA), both in absolute concentration and percentage (dd-cfDNA%), as well as total cell-free DNA (cfDNA), may be predictive of subsequent BLAD development. METHODS: We included patients who underwent bilateral lung transplantation between May 2021 and September 2023. Blood samples collected between 3 and 9 months post-transplantation were analysed for dd-cfDNA%, dd-cfDNA concentration (copies/mL), and estimated total cfDNA (copies/mL). BLAD was defined by failure to achieve both FEV1 and FVC &gt;=80 % of predicted values within the first year. RESULTS: A total of 158 samples from 37 patients were analysed. Ten patients (27 %) met the BLAD criteria. Those with BLAD had significantly higher dd-cfDNA levels (median: 39 cp/mL) compared to non-BLAD patients (26 cp/mL; p = 0.01). Similarly, total cfDNA levels were significantly elevated in the BLAD group (22,809 cp/mL vs. 13,840 cp/mL; p = 0.002). However, dd-cfDNA% did not differ significantly (0.23 % vs. 0.15 %; p = 0.2). CONCLUSION: Elevated absolute dd-cfDNA and total cfDNA levels in the early post-transplant period were associated with BLAD, suggesting that cfDNA may serve as a potential predictive biomarker. These findings support the potential of cfDNA-based biomarkers to enhance early detection of graft dysfunction, warranting validation in larger cohorts.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Transplant Immunology

ISSN

0966-3274

e-ISSN

1878-5492

Svazek periodika

92

Číslo periodika v rámci svazku

September

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

102245

Kód UT WoS článku

001510112100001

EID výsledku v databázi Scopus

2-s2.0-105007061071